Skip to main content

Table 1 Patient characteristics

From: Y90 Radioembolization in chemo-refractory metastastic, liver dominant colorectal cancer patients: outcome assessment applying a predictive scoring system

Patient characteristics
 Female n = 36 33,9 %
 Male n = 70 66,1 %
 Age (median (range), years) 62.5 (33.0 -76.0)
 Karnofsky index (median (range), %) 80 (60–100)  
Pretreatment characteristics
 Prior resection or radiofrequency ablation n = 30 28 %
 Prior chemotherapy agents
  Oxaliplatin (+5-fluorouracil) n = 79 75 %
  Irinotecan (+5-fluorouracil) n = 89 84 %
  Capecitabine n = 27 25 %
  Bevacizumab n = 67 63 %
  Cetuximab n = 51 48 %
  Other n = 7 7 %
Overall chemotherapy lines (median (range)) 3 (1–5)  
  1st Line n = 9 8 %
  2nd Line n = 35 33 %
  3rd Line n = 34 32 %
  4th Line and beyond n = 28 26 %
Tumor characteristics
 UICC stage (median (range)) 4 (1–4)  
 Grading (median (range)) 2 (1–4)  
 Synchronous lymphatic metastases n = 80 75 %
 Extrahepatic tumor sites prior to radioembolization n = 30 28 %
  Solitary/oligonodular lung metastases n = 1 1 %
  Diffuse lung metastases n = 15 14 %
  Lymphatic metastases n = 17 16 %
  Bone metastases n = 3 3 %
 Hepatic tumor load (median (range), %) 15.7 (1.0–63.0)
 CEA serum level (median (range), ng/ml) 130.1 (2.7–8713.3)
 CA19-9 serum level (median (range), U/ml) 192.7 (0.3–32206.0)
Radioembolization procedures n = 178 100 %
 Bilobar (total liver) n = 12 7 %
 Unilobar n = 52 30 %
 Sequential lobar n = 114 64 %
 Treatment sessions per patient (median (range)) 2 (1–5)  
 Total activity per patient (median (range), MBq) 1725.0 (200.0–3650)